QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
NASDAQ:ME

23andMe (ME) Stock Price, News & Analysis

$0.53
+0.02 (+4.33%)
(As of 03:03 PM ET)
Today's Range
$0.52
$0.55
50-Day Range
$0.40
$0.81
52-Week Range
$0.40
$2.32
Volume
3.28 million shs
Average Volume
7.10 million shs
Market Capitalization
$257.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.75

23andMe MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
227.0% Upside
$1.75 Price Target
Short Interest
Healthy
11.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of 23andMe in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$132,991 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.92 out of 5 stars

Medical Sector

420th out of 939 stocks

Pharmaceutical Preparations Industry

195th out of 433 stocks

ME stock logo

About 23andMe Stock (NASDAQ:ME)

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

ME Stock Price History

ME Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
How to verify a data breach
ME Apr 2024 0.500 call
ME Apr 2024 1.500 put
See More Headlines
Receive ME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
3/28/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
769
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.75
High Stock Price Target
$1.75
Low Stock Price Target
$1.75
Potential Upside/Downside
+242.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-311,660,000.00
Net Margins
-210.48%
Pretax Margin
-210.71%

Debt

Sales & Book Value

Annual Sales
$299.49 million
Book Value
$1.55 per share

Miscellaneous

Free Float
349,873,000
Market Cap
$246.48 million
Optionable
Not Optionable
Beta
1.28
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Ms. Anne Wojcicki
    Co-Founder, CEO, President & Chair of the Board
  • Mr. Joseph Selsavage (Age 61)
    Interim CFO & Accounting Officer
    Comp: $574.56k
  • Ms. Kathy L. Hibbs Esq. (Age 60)
    J.D., Chief Administrative Officer & Corporate Secretary
    Comp: $699.8k
  • Mr. Guy Chayoun
    Vice President & Interim General Counsel
  • Ms. Katie Watson (Age 46)
    Vice President of Communications
  • Mr. Jonathan Ward
    Chief Marketing Officer
  • Mr. Reza Afkhami M.B.A.
    Chief Corporate Development Officer
  • Ms. Savita Pillai
    Vice President of People
  • Dr. Jennifer Low (Age 55)
    Head of Therapeutics Development
  • Mr. Kent Hillyer (Age 56)
    Vice President of Consumer Operations

ME Stock Analysis - Frequently Asked Questions

Should I buy or sell 23andMe stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ME shares.
View ME analyst ratings
or view top-rated stocks.

What is 23andMe's stock price target for 2024?

1 brokerages have issued 12-month price objectives for 23andMe's shares. Their ME share price targets range from $1.75 to $1.75. On average, they predict the company's share price to reach $1.75 in the next twelve months. This suggests a possible upside of 227.0% from the stock's current price.
View analysts price targets for ME
or view top-rated stocks among Wall Street analysts.

How have ME shares performed in 2024?

23andMe's stock was trading at $0.9135 at the beginning of 2024. Since then, ME stock has decreased by 41.4% and is now trading at $0.5351.
View the best growth stocks for 2024 here
.

When is 23andMe's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024.
View our ME earnings forecast
.

How were 23andMe's earnings last quarter?

23andMe Holding Co. (NASDAQ:ME) posted its quarterly earnings data on Wednesday, February, 7th. The company reported ($0.17) earnings per share (EPS) for the quarter. The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $56.30 million. 23andMe had a negative net margin of 210.48% and a negative trailing twelve-month return on equity of 52.99%.

What ETFs hold 23andMe's stock?

ETFs with the largest weight of 23andMe (NASDAQ:ME) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Global X Telemedicine & Digital Health ETF (EDOC).

What guidance has 23andMe issued on next quarter's earnings?

23andMe updated its FY 2024 earnings guidance on Wednesday, February, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $215.0 million-$220.0 million, compared to the consensus revenue estimate of $245.5 million.

Who are 23andMe's major shareholders?

23andMe's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.71%), Vanguard Group Inc. (4.67%), Voya Investment Management LLC (1.15%), Northern Trust Corp (0.56%), Charles Schwab Investment Management Inc. (0.51%) and Wittenberg Investment Management Inc. (0.29%). Insiders that own company stock include Kathy L Hibbs, Kenneth J Hillan and William G Richards.
View institutional ownership trends
.

How do I buy shares of 23andMe?

Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ME) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners